Mucosal Response in Immunocompromised Host

NCT ID: NCT01109914

Last Updated: 2015-03-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 51 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-04-30
• Study Completion Date: 2015-03-31

Brief Summary

The aim of this study is to verify whether vaccination with Dukoral® (SBL Vaccines) induces an immune response in renal transplant recipients on prednisolone in combination with either a calcineurin inhibitor CNI) or mycophenolate mofetil (MMF).

Detailed Description

BACKGROUND:

LT-ETEC is the most common cause of travelers' diarrhoea. Dukoral® (SBL Vaccines) reduces the severity and duration of LT-ETEC induced diarrhea. Dehydration due to diarrhea poses a risk to the health of renal transplant recipients. Therefore Dukoral may benefit this group of travelers.

AIM OF THIS STUDY:

Primary objective: To verify whether vaccination with Dukoral® (SBL Vaccines) induces an immune response in renal transplant recipients on prednisolone in combination with either a calcineurin inhibitor (cyclosporine or tacrolimus) or mycophenolate mofetil.

Secondary objective: To evaluate to what extent, the immune response differs, depending on the use of different classes of immunosuppressive drugs (CNI or MMF).

STUDY DESIGN:

Single center interventional study.

Population: The population base of the study consists of adult renal transplant recipients who received their transplant at our medical center. The control population consists of the healthy partners and siblings of the renal transplant recipients. We intend to include 10 healthy volunteers and 60 renal transplant recipients (20 on prednisolone and a CNI and 20 on prednisolone and MMF).

Intervention: Dukoral® (SBL Vaccines) will be administered orally at baseline (day 0) and at day 14.

Laboratory analysis: Serum CTB antibody (ELISA), Vibriocidal assay. The analysis is performed at Crucell.

Statistical analysis: No formal sample-size calculation was performed. The crude outcome estimates will be adjusted for variables that may influence the outcome (age, time after transplantation, past treatment for transplant rejection, current renal function, cumulative prednisolone dose, serum concentration (i.e. area under the curve) of CNI and MMF.

Note: the study intended to also recruit a study arm consisting of patients on a mTORi. Recruitment for this study arm was unsuccesful due to the scarcity of elligible patients.

Conditions

Kidney Transplantation; Immunity

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Renal transplant recipients (MMF)

Renal transplant recipients using prednisolone and mycophenolate mofetil (MMF) but no other immunosuppressive drug.

Intervention: vaccination with Dukoral

Group Type: EXPERIMENTAL

Dukoral

Intervention Type: BIOLOGICAL

Two oral doses of Dukoral® (SBL Vaccines) will be administered (day 0 and day 14). Each dosage contains 3 ml of suspension in a vial and 5.6 g of effervescent granules in a sachet. Each dosage (3 ml) contains: A total of 100000 million bacteria of the following strains:

• Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 25x1000 million bacteria*
• Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 25x1000 million bacteria*
• Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 25x1000 million bacteria*
• Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 25x1000 million bacteria*
• Recombinant cholera toxin B subunit (rCTB) 1 mg (produced in V. cholerae O1 Inaba, classical biotype strain 213)

Renal transplant recipients (CNI)

Renal transplant recipients using prednisolone and a calcineurin inhibitor (cyclosporine or tacrolimus) but no other immunosuppressive drug.

Intervention: vaccination with Dukoral

Group Type: EXPERIMENTAL

Dukoral

Intervention Type: BIOLOGICAL

Two oral doses of Dukoral® (SBL Vaccines) will be administered (day 0 and day 14). Each dosage contains 3 ml of suspension in a vial and 5.6 g of effervescent granules in a sachet. Each dosage (3 ml) contains: A total of 100000 million bacteria of the following strains:

• Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 25x1000 million bacteria*
• Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 25x1000 million bacteria*
• Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 25x1000 million bacteria*
• Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 25x1000 million bacteria*
• Recombinant cholera toxin B subunit (rCTB) 1 mg (produced in V. cholerae O1 Inaba, classical biotype strain 213)

Healthy volunteers

Healthy volunteers (partners, brothers or sisters of the renal transplant recipients).

Intervention: vaccination with Dukoral

Group Type: EXPERIMENTAL

Dukoral

Intervention Type: BIOLOGICAL

Two oral doses of Dukoral® (SBL Vaccines) will be administered (day 0 and day 14). Each dosage contains 3 ml of suspension in a vial and 5.6 g of effervescent granules in a sachet. Each dosage (3 ml) contains: A total of 100000 million bacteria of the following strains:

• Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 25x1000 million bacteria*
• Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 25x1000 million bacteria*
• Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 25x1000 million bacteria*
• Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 25x1000 million bacteria*
• Recombinant cholera toxin B subunit (rCTB) 1 mg (produced in V. cholerae O1 Inaba, classical biotype strain 213)

Interventions

Dukoral

Two oral doses of Dukoral® (SBL Vaccines) will be administered (day 0 and day 14). Each dosage contains 3 ml of suspension in a vial and 5.6 g of effervescent granules in a sachet. Each dosage (3 ml) contains: A total of 100000 million bacteria of the following strains:

• Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 25x1000 million bacteria*
• Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 25x1000 million bacteria*
• Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 25x1000 million bacteria*
• Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 25x1000 million bacteria*
• Recombinant cholera toxin B subunit (rCTB) 1 mg (produced in V. cholerae O1 Inaba, classical biotype strain 213)

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Above 18 years of age
• Informed consent

• Above 18 years of age
• Creatinin clearance ≥ 40 ml/min measured in the 6 months prior to inclusion
• Stable renal function for 1 year prior to inclusion
• Stable immunosuppressive regimen of a CNI, MMF or mTORi combined with prednisolone for at least 3 months prior to inclusion
• Informed Consent

Exclusion Criteria

• History of an auto-immune disease (SLE, ANCA associated vasculitis, Goodpasture, Henoch Schonlein, cryoglobulinemia, secondary vasculitis, polyarteritis nodosa and immunodeficiency disorders like IgA deficiency)
• Chronic infection
• Past vaccination with Dukoral or another cholera or ETEC vaccine
• History of infection with Vibrio cholerae
• Episode of diarrhoea in the 6 months prior to inclusion
• Allergy to vaccine-specific components
• History of a severe allergic reaction to any vaccine
• Treatment with blood products in the 3 months prior to inclusion
• Current pregnancy or breastfeeding
• Premenopausal women not willing to use contraceptives during the first 60 days after vaccination
• Use of any immunosuppressive drug

RENAL TRANSPLANT RECIPIENTS

• History of an auto-immune disease (SLE, ANCA associated vasculitis, Goodpasture, Henoch Schonlein, cryoglobulinemia, secondary vasculitis, polyarteritis nodosa and immunodeficiency disorders like IgA deficiency)
• Chronic infection
• Treatment for rejection of the transplant in the past 1 year prior to inclusion
• Past vaccination with Dukoral or another cholera or ETEC vaccine
• History of infection with Vibrio cholerae
• Episode of diarrhoea in the 6 months prior to inclusion
• Allergy to vaccine-specific components
• History of a severe allergic reaction to any vaccine
• Treatment with blood products in the 3 months prior to inclusion
• Current pregnancy or breastfeeding
• Premenopausal women not willing to use contraceptives during the first 60 days after vaccination
• Use of an immunosuppressive drug other than CNI, MMF, mTORi or prednisolone at the the time of inclusion

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Crucell B.V., Leiden, the Netherlands

UNKNOWN

Sponsor Role: collaborator

Leiden University Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Darius Soonawala

Drs

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Leo G Visser, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Leiden University Medical Center

Darius Soonawala, MD

Role: STUDY_DIRECTOR

Leiden University Medical Center

O W Bredewold, MD

Role: STUDY_CHAIR

Leiden University Medical Center

J W de Fijter, Prof PhD

Role: STUDY_CHAIR

Leiden University Medical Center

Marjolein AC Uijlings

Role: STUDY_CHAIR

Leiden University Medical Center

Emile FF Jonker, MD

Role: STUDY_CHAIR

Leiden University Medical Center

Locations

Leiden Univeristy Medical Centre

Leiden, South Holland, Netherlands

Countries

Netherlands

References

Jonker EFF, Uijlings MAC, Visser LG, Soonawala D. Comparison of the immunogenicity of Dukoral(R) oral cholera vaccine between renal transplant recipients on either a calcineurin inhibitor or mycophenolate - A controlled trial. Vaccine. 2019 May 21;37(23):3133-3139. doi: 10.1016/j.vaccine.2019.04.010. Epub 2019 Apr 24.

Reference Type: DERIVED

PMID: 31029516 (View on PubMed)

Other Identifiers

MICH P10.011

Identifier Type: -

Identifier Source: org_study_id